US Bancorp DE Trims Position in Ascendis Pharma A/S (NASDAQ:ASND)

US Bancorp DE lessened its stake in Ascendis Pharma A/S (NASDAQ:ASND) by 12.0% in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 1,063 shares of the biotechnology company’s stock after selling 145 shares during the quarter. US Bancorp DE’s holdings in Ascendis Pharma A/S were worth $114,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Clearstead Advisors LLC acquired a new position in Ascendis Pharma A/S in the first quarter valued at about $66,000. Brown Advisory Inc. grew its position in Ascendis Pharma A/S by 5.9% in the 1st quarter. Brown Advisory Inc. now owns 466,372 shares of the biotechnology company’s stock valued at $50,004,000 after buying an additional 26,080 shares during the last quarter. Barclays PLC grew its position in Ascendis Pharma A/S by 21.5% in the 1st quarter. Barclays PLC now owns 68,902 shares of the biotechnology company’s stock valued at $7,388,000 after buying an additional 12,195 shares during the last quarter. CM Wealth Advisors LLC acquired a new stake in Ascendis Pharma A/S in the first quarter valued at $1,319,000. Finally, SG Americas Securities LLC raised its stake in Ascendis Pharma A/S by 121.4% in the 1st quarter. SG Americas Securities LLC now owns 46,347 shares of the biotechnology company’s stock valued at $4,969,000 after purchasing an additional 25,417 shares during the last quarter.

Ascendis Pharma A/S Stock Up 1.5 %

Shares of Ascendis Pharma A/S stock opened at $98.02 on Friday. The company has a quick ratio of 3.32, a current ratio of 4.08 and a debt-to-equity ratio of 2.87. Ascendis Pharma A/S has a 12 month low of $64.33 and a 12 month high of $134.52. The business has a fifty day simple moving average of $90.59 and a 200 day simple moving average of $93.97. The stock has a market cap of $5.62 billion, a PE ratio of -9.34 and a beta of 0.51.

Wall Street Analyst Weigh In

A number of research analysts recently commented on ASND shares. StockNews.com downgraded Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a research note on Wednesday, August 16th. Morgan Stanley reiterated an “equal weight” rating and issued a $109.00 price objective on shares of Ascendis Pharma A/S in a research report on Monday, August 7th. Finally, Wedbush raised their target price on Ascendis Pharma A/S from $186.00 to $187.00 in a research report on Friday, June 2nd. One analyst has rated the stock with a sell rating, three have issued a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $146.50.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company also develops TransCon Growth Hormone for treating pediatric GHD, adult GHD, and turner syndrome; TransCon Parathyroid Hormone for adult patients with hypoparathyroidism; and TransCon C-type natriuretic peptide for achondroplasia.